Table 5. Numbers of preparations and active agents and percentages of anti-hypertensive medications groups.
| Non-T2D | Non-T2D | Future incident T2D | Incident T2D | Prevalent T2D | Prevalent T2D | |
|---|---|---|---|---|---|---|
| ● BL | ●● FUP | BL | FUP | BL | FUP | |
| number of preparations * | 1.6 (1.5; 1.6) | 2.0 (1.9; 2.0) | 1.7 (1.6; 1.9) | 2.1 (2.0; 2.3) | 2.0 (1.8; 2.1) | 2.4 (2.2; 2.5) |
| number of diff. active components | 1.9 (1.8; 2.0) | 2.4 (2.3; 2.5) | 2.1 (1.9; 2.3) | 2.7 (2.5; 2.9) | 2.4 (2.2; 2.5) | 2.9 (2.8; 3.1) |
| ** % beta blocking agents | 54.2 (51.5; 57.0) | 63.6 (61.0; 66.3) | 49.9 (42.3; 57.5) | 62.7 (55.3; 70.0) | 47.8 (42.7; 53.0) | 65.7 (60.8; 70.6) |
| % ACE inhibitors | 39.4 (36.7; 42.1) | 44.6 (41.8; 47.3) | 46.7 (39.2; 54.3) | 60.6 (53.2; 68.0) | 61.8 (56.8; 66.8) | 64.9 (60.0; 69.8) |
| % diuretics | 36.7 (34.1; 39.3) | 49.3 (46.6; 52.1) | 43.0 (35.5; 50.6) | 59.2 (51.7; 66.6) | 48.1 (43.0; 53.3) | 62.9 (57.9; 67.9) |
| % angiotensin antagonists | 16.0 (14.0; 18.0) | 29.9 (27.4; 32.4) | 10.6 (05.9; 15.3) | 23.2 (16.8; 29.6) | 13.1 (09.6; 16.5) | 23.1 (18.7; 27.4) |
| % calcium channel blockers | 31.6 (29.1; 34.2) | 38.5 (35.8; 41.2) | 37.4 (30.0; 44.7) | 35.9 (28.6; 43.2) | 40.5 (35.4; 45.6) | 46.0 (40.8; 51.1) |
| % other anti-hypertensives | 5.7 (4.4; 7.0) | 5.3 (4.1; 6.5) | 9.7 (5.2; 14.3) | 6.8 (3.0; 10.6) | 12.8 (9.4; 16.3) | 12.7 (9.3; 16.2) |
Numbers are weighted and given with 95% CI.
●BL: Baseline
●●FUP: Follow-Up
*including combinations of different active agents
**percentage of study participants who used at least one active component from this group